HER2特异性嵌合抗原受体修饰的病毒特异性T细胞治疗进展性胶质母细胞瘤:一项1期剂量递增试验
这项开放标签1期剂量递增研究纳入17例进展性HER2阳性胶质母细胞瘤患者,接受自体HER2-CAR病毒特异性T细胞(VST)单药治疗,剂量为1×10^6/m^2至1×10^8/m^2,未进行淋巴细胞清除。输注耐受良好,无剂量限制性毒性;16例可评估患者中1例部分缓解持续超过9个月,7例疾病稳定8周至29个月,8例进展。中位总生存期自首次T细胞输注为11.1个月(95%CI 4.1-27.2个月),自诊断起为24.5个月(95%CI 17.2-34.6个月)。
要点
- 自体HER2-CAR VSTs单药输注耐受良好,未出现剂量限制性毒性。
- 16例可评估患者中1例部分缓解持续超过9个月,7例疾病稳定8周至29个月。
- 中位总生存期自首次输注为11.1个月(95%CI 4.1-27.2个月)。
核心结论
- 输注自体HER2-CAR VSTs是安全的,且可能与进展性胶质母细胞瘤患者的临床获益相关。
- 有必要在2b期研究中进一步评估HER2-CAR VSTs作为单药或与其他免疫调节方法联合治疗胶质母细胞瘤。
研究设计与样本
- 开放标签1期剂量递增研究,在贝勒医学院、休斯敦卫理公会医院和得克萨斯儿童医院开展。
- 纳入2011年7月25日至2014年4月21日期间进展性HER2阳性胶质母细胞瘤患者,随访时间10周至29个月(中位8个月)。
- 共17例患者接受1次或多次自体HER2-CAR VSTs输注(1×10^6/m^2至1×10^8/m^2),未进行预先淋巴细胞清除。
- 主要终点为可行性和安全性,关键次要终点为T细胞持久性和抗胶质母细胞瘤活性。
主要发现
- 17例患者中8例女性、9例男性;10例≥18岁(中位年龄60岁,范围30-69岁),7例<18岁(中位年龄14岁,范围10-17岁)。
- 输注耐受良好,无剂量限制性毒性。
- 定量实时聚合酶链反应可在输注后外周血中检测到HER2-CAR VSTs长达12个月。
- 16例可评估患者(9例成人、7例儿童)中,1例部分缓解持续超过9个月,7例疾病稳定8周至29个月,8例在T细胞输注后进展。
- 3例疾病稳定患者随访24至29个月仍存活且无进展证据。
临床怎么用
- 作者认为,输注自体HER2-CAR VSTs是安全的,且可能与进展性胶质母细胞瘤患者的临床获益相关。
- 作者认为,有必要在2b期研究中进一步评估HER2-CAR VSTs作为单药或与其他免疫调节方法联合治疗胶质母细胞瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. OBJECTIVE: To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)-modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity. DESIGN, SETTING, AND PARTICIPANTS: In this open-label phase 1 dose-escalation study conducted at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, patients with progressive HER2-positive glioblastoma were enrolled between July 25, 2011, and April 21, 2014. The duration of follow-up was 10 weeks to 29 months (median, 8 months). INTERVENTIONS: Monotherapy with autologous VSTs specific for cytomegalovirus, Epstein-Barr virus, or adenovirus and genetically modified to express HER2-CARs with a CD28.ζ-signaling endodomain (HER2-CAR VSTs). MAIN OUTCOMES AND MEASURES: Primary end points were feasibility and safety. The key secondary end points were T-cell persistence and their antiglioblastoma activity. RESULTS: A total of 17 patients (8 females and 9 males; 10 patients ≥18 years [median age, 60 years; range, 30-69 years] and 7 patients <18 years [median age, 14 years; range, 10-17 years]) with progressive HER2-positive glioblastoma received 1 or more infusions of autologous HER2-CAR VSTs (1 × 106/m2 to 1 × 108/m2) without prior lymphodepletion. Infusions were well tolerated, with no dose-limiting toxic effects. HER2-CAR VSTs were detected in the peripheral blood for up to 12 months after the infusion by quantitative real-time polymerase chain reaction. Of 16 evaluable patients (9 adults and 7 children), 1 had a partial response for more than 9 months, 7 had stable disease for 8 weeks to 29 months, and 8 progressed after T-cell infusion. Three patients with stable disease are alive without any evidence of progression during 24 to 29 months of follow-up. For the entire study cohort, median overall survival was 11.1 months (95% CI, 4.1-27.2 months) from the first T-cell infusion and 24.5 months (95% CI, 17.2-34.6 months) from diagnosis. CONCLUSIONS AND RELEVANCE: Infusion of autologous HER2-CAR VSTs is safe and can be associated with clinical benefit for patients with progressive glioblastoma. Further evaluation of HER2-CAR VSTs in a phase 2b study is warranted as a single agent or in combination with other immunomodulatory approaches for glioblastoma.
引用
- Ahmed N, Brawley V, Hegde M, et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017. PMID: 28426845. doi:10.1001/jamaoncol.2017.0184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。